# A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts

> **NCT01012752** · PHASE3 · UNKNOWN · sponsor: **Roxall Medizin** · enrollment: 150 (estimated)

## Conditions studied

- Allergic Rhinitis
- Allergic Conjunctivitis

## Interventions

- **BIOLOGICAL:** modified allergen extract
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01012752
- **Lead sponsor:** Roxall Medizin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012752, "A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01012752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*